Mena FN

Revolution Medicines Begins Treating Patients In Rasolute 305, A Phase 3 Clinical Trial Evaluating Zoldonrasib In Combination With Chemotherapy As A First Line Treatment For ...

(MENAFN- GlobeNewsWire - Nasdaq) REDWOOD CITY, Calif., June 23, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with ...
manilatimes

Revolution Medicines Begins Treating Patients in RASolute 305, a Phase 3 Clinical Trial Evaluating Zoldonrasib in Combination with Chemotherapy as a First Line Treatment for ...

REDWOOD CITY, Calif., June 23, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today ...
Investing News Network

Revolution Medicines Begins Treating Patients in RASolute 305, a Phase 3 Clinical Trial Evaluating Zoldonrasib in Combination with Chemotherapy as a First Line Treatment for ...

Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it has begun treating patients in RASolute 305, ...
IEEE

Application of HEC-RAS and Satellite Imagery in Flood Risk Estimation for Rural Area in Thailand

Abstract: The world is facing unavoidable disaster challenges, especially floods in Thailand, these inundations have been becoming increasingly difficult to manage each year. Therefore, a preliminary ...
For Construction Pros

Caterpillar Updates Excavator Line with Grade Tech, New Interface and Payload Upgrades

Caterpillar updates its 2025 excavator lineup with integrated 2D and optional 3D Grade technology, a new user interface and expanded payload features to boost efficiency and simplify operation.